Exubera and Novolog drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Exubera (insulin recombinant human) and Novolog (insulin aspart recombinant). Common drug interactions include chest pain among females and blood glucose decreased among males.
The phase IV clinical study analyzes what interactions people have when they take Exubera and Novolog. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.
What is Exubera?
Exubera has active ingredients of insulin recombinant human. eHealthMe is studying from 448 Exubera users. Check the latest studies of Exubera.
What is Novolog?
Novolog has active ingredients of insulin aspart recombinant. It is often used in diabetes. eHealthMe is studying from 56,160 Novolog users. Check the latest studies of Novolog.
11 people who take Exubera and Novolog together, and have interactions are studied.
What are the common drug interactions of Exubera and Novolog, by gender? *:
female:
- Chest pain
- Face oedema (swelling of face)
- Abdominal pain upper
- Asthma
- Diastolic dysfunction
- Dyspnoea (difficult or laboured respiration)
- Hyperhidrosis (abnormally increased sweating)
- Nausea (feeling of having an urge to vomit)
- Vomiting
male:
- Blood glucose decreased
- Chest injury
- Fall
- Feeling cold
- Gait disturbance
- Hypercholesterolaemia (high levels of cholesterol in the blood)
- Hyperglycaemia (high blood sugar)
- Hyperhidrosis (abnormally increased sweating)
- Injection site pain
- Lung disorder (lung disease)
What are the common drug interactions of Exubera and Novolog, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
- Face oedema (swelling of face)
30-39:
n/a
40-49:
- Drug ineffective
- Dysgeusia (disorder of the sense of taste)
- Hyperglycaemia (high blood sugar)
- Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
50-59:
n/a
60+:
- Hyperhidrosis (abnormally increased sweating)
- Blood glucose decreased
- Chest pain
- Diastolic dysfunction
- Dyspnoea (difficult or laboured respiration)
- Forced expiratory volume decreased (decreased lung expired air volume)
- Nausea (feeling of having an urge to vomit)
- Vomiting
- Disorientation (disability in which the senses of time, direction, and recognition of people and places)
- Disturbance in attention
What are the existing conditions these people have? *
- Type 2 Diabetes: 5 people, 45.45%
- Type 1 Diabetes: 2 people, 18.18%
* Approximation only. Some reports may have incomplete information.
Do you take Exubera and Novolog?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Exubera and Novolog:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exubera:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Novolog:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exubera and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Novolog and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on insulin recombinant human and insulin aspart recombinant (the active ingredients of Exubera and Novolog, respectively), and Exubera and Novolog (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Xyrem cause Calcinosis? - a second ago
- Could Rocephin cause Calcinosis? - 3 seconds ago
- Could Vecuronium Bromide cause Tendonitis? - 3 seconds ago
- Could Rapamune cause Calcinosis? - 5 seconds ago
- Could Reclast cause Calcinosis? - 7 seconds ago
- Could Tacrolimus cause Calcinosis? - 7 seconds ago
- Could Renagel cause Calcinosis? - 8 seconds ago
- Could Taxol cause Calcinosis? - 9 seconds ago
- Could Thalomid cause Calcinosis? - 10 seconds ago
- Could Rezulin cause Calcinosis? - 11 seconds ago